[Clinical effects of cefoxitin on infections in digestive diseases].
Cefoxitin (CFX) was administrated to a total of 12 hospitalized patients with digestive diseases, in combination with aminoglycosides. The following results were obtained: Clinical effects of CFX on 12 cases were "excellent" in 4 cases, "good" in 5, "fair" in 1 and "unknown" in 2, with the efficacy rate of 75%. All 4 cases who developed septicemia with underlying severe diseases showed "excellent" effect to CFX. Clinical results of 8 cases with hepatic biliary tract infections were "good" in 5, "fair" in 1 and "unknown" in 2, with the efficacy rate in 62.5%. As for side effects, an allergic reaction was observed in 1 case, and it is suggested renal function should be monitored carefully in a case of combination use with aminoglycosides.
D000368:Aged; D001424:Bacterial Infections / Q000188:drug therapy*; D001660:Biliary Tract Diseases / Q000188:drug therapy; D002440:Cefoxitin / Q000008:administration & dosage / Q000627:therapeutic use*; D002764:Cholecystitis / Q000188:drug therapy; D003982:Dibekacin / Q000008:administration & dosage; D004066:Digestive System Diseases / Q000188:drug therapy*; D004359:Drug Therapy, Combination; D005260:Female; D042882:Gallstones / Q000188:drug therapy; D005839:Gentamicins / Q000008:administration & dosage; D006801:Humans; D008100:Liver Abscess / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D018805:Sepsis / Q000188:drug therapy
D005839:Gentamicins; D003982:Dibekacin; D002440:Cefoxitin